Literature DB >> 34790370

Combination of the ratio between metastatic and harvested lymph nodes and negative lymph node count as a prognostic indicator in advanced gastric cancer: a retrospective cohort study.

Jianlong Jiang1, Jingyao Chen1, Hao Zhang2, Xionghui Rao3, Tengfei Hao1, Mingzhe Li1, Changhua Zhang1, Wenhui Wu1, Yulong He1.   

Abstract

BACKGROUND: The aim of our study was to examine the impact of the combination of the ratio between metastatic and harvested lymph nodes (RML) and negative lymph node (NLN) count on overall survival (OS) in patients with advanced gastric cancer (GC).
METHODS: The clinicopathological data of 2,952 advanced GC patients who received curative resection between 1994 and 2015 were collected. They were divided into four groups according to the RML: 0, 0-0.1, 0.1-0.4, and >0.4. We distinguished survival differences through Kaplan-Meier analysis among the subgroups to investigate the impacts of the RML on OS in advanced GC patients. OS was examined according to clinicopathological variables. Spearman's correlation coefficient was used to assess the relationships between the RML and metastatic lymph node (MLN) count and NLN count.
RESULTS: A total of 1,182 patients were enrolled into the study. The median follow-up time was 39 months (interquartile range 20 to 68 months). The 5-year OS rate of all 1,182 GC patients was 54.4%. Kaplan-Meier survival analysis showed that the median OS declined significantly with increasing RML (5-year survival rate 81.2% vs. 69.1% vs. 42.8% vs. 13.1%, P<0.001). As the NLN count increased, the survival rate of GC patients increased (5-year survival rate 12.8% vs. 25.2% vs. 60.2%, P<0.05). The RML, not NLN count, was identified as an independent factor for OS (P<0.001) through multivariate analysis. Spearman correlation analysis suggested that the RML was positively correlated with the number of MLNs (ρ=0.973, P<0.001) and inversely associated with the NLN count (ρ=-0.513, P<0.001).
CONCLUSIONS: The RML is an independent prognostic predictor of OS in advanced GC patients, and the NLN count may serve as a supplementary strategy for the present tumor-node-metastasis (TNM) classification to further improve the prognostic prediction efficiency. The combination of the RML and NLN count should be an important predictor for current clinical applications. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Gastric cancer (GC); metastatic lymph node (MLN); negative lymph node (NLN); prognosis

Year:  2021        PMID: 34790370      PMCID: PMC8576250          DOI: 10.21037/jgo-21-212

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  26 in total

1.  Mesorectal lymph nodes: their location and distribution within the mesorectum.

Authors:  Boris Topor; Robert Acland; Valentina Kolodko; Susan Galandiuk
Journal:  Dis Colon Rectum       Date:  2003-06       Impact factor: 4.585

2.  Lymph node recoveries from 2427 pT3 colorectal resection specimens spanning 45 years: recommendations for a minimum number of recovered lymph nodes based on predictive probabilities.

Authors:  Neal S Goldstein
Journal:  Am J Surg Pathol       Date:  2002-02       Impact factor: 6.394

3.  Enhancement the prediction of postoperative survival in gastric cancer by combining the negative lymph node count with ratio between positive and examined lymph nodes.

Authors:  Jingyu Deng; Han Liang; Dianchang Wang; Dan Sun; Xuewei Ding; Yi Pan; Xiangyu Liu
Journal:  Ann Surg Oncol       Date:  2009-12-29       Impact factor: 5.344

4.  Negative lymph node count as an independent prognostic factor in stage III patients after curative gastrectomy: A retrospective cohort study based on a multicenter database.

Authors:  Nannan Zhang; Jingyu Deng; Wei Wang; Zhe Sun; Zhenning Wang; Huimian Xu; Zhiwei Zhou; Han Liang
Journal:  Int J Surg       Date:  2019-12-23       Impact factor: 6.071

5.  Risk factors predictive of lymph node metastasis in depressed early gastric cancer.

Authors:  Nobutsugu Abe; Takashi Watanabe; Kazufumi Suzuki; Hiromichi Machida; Hiroshi Toda; Yuzo Nakaya; Tadahiko Masaki; Toshiyuki Mori; Masanori Sugiyama; Yutaka Atomi
Journal:  Am J Surg       Date:  2002-02       Impact factor: 2.565

6.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

7.  Clinical impact of metastatic lymph node ratio in advanced gastric cancer.

Authors:  Chikara Kunisaki; Hiroshi Shimada; Masato Nomura; Goro Matsuda; Yuichi Otsuka; Hidetaka Ono; Hirotoshi Akiyama
Journal:  Anticancer Res       Date:  2005 Mar-Apr       Impact factor: 2.480

8.  Hospital lymph node examination rates and survival after resection for colon cancer.

Authors:  Sandra L Wong; Hong Ji; Brent K Hollenbeck; Arden M Morris; Onur Baser; John D Birkmeyer
Journal:  JAMA       Date:  2007-11-14       Impact factor: 56.272

9.  Lymph node counts in the upper abdomen: anatomical basis for lymphadenectomy in gastric cancer.

Authors:  P K Wagner; A Ramaswamy; J Rüschoff; P Schmitz-Moormann; M Rothmund
Journal:  Br J Surg       Date:  1991-07       Impact factor: 6.939

10.  The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients.

Authors:  Alberto Marchet; Simone Mocellin; Alessandro Ambrosi; Paolo Morgagni; Domenico Garcea; Daniele Marrelli; Franco Roviello; Giovanni de Manzoni; Annamaria Minicozzi; Giovanni Natalini; Francesco De Santis; Luca Baiocchi; Arianna Coniglio; Donato Nitti
Journal:  Ann Surg       Date:  2007-04       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.